Hydroxymethylglutaryl-coenzyme A reductase inhibitor: Difference between revisions
imported>David E. Volk m (wikilink to 3-hydroxy-3-methyl-glutaryl CoA) |
imported>Robert Badgett (→Effectiveness: Added JUPITER trial) |
||
| Line 12: | Line 12: | ||
==Effectiveness== | ==Effectiveness== | ||
[[Statin]] therapy benefits about 1 of every 24 diabetic patients who use the treatment for 5 years if they are similar to the patients in the [[meta-analysis]] by Kearney et al ([[Number needed to treat]] is 24).<ref name="pmid18191683">{{cite journal |author=Kearney PM, Blackwell L, Collins R, ''et al'' |title=Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis |journal=Lancet |volume=371 |issue=9607 |pages=117–25 |year=2008 |pmid=18191683 |doi=10.1016/S0140-6736(08)60104-X}}</ref> | [[Statin]] therapy benefits about 1 of every 24 diabetic patients who use the treatment for 5 years if they are similar to the patients in the [[meta-analysis]] by Kearney et al ([[Number needed to treat]] is 24).<ref name="pmid18191683">{{cite journal |author=Kearney PM, Blackwell L, Collins R, ''et al'' |title=Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis |journal=Lancet |volume=371 |issue=9607 |pages=117–25 |year=2008 |pmid=18191683 |doi=10.1016/S0140-6736(08)60104-X}}</ref> | ||
[[Statin]] therapy benefits about 1 of every 170 patients with [[LDL cholesterol]] less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity [[C-reactive protein]] levels of 2.0 mg per liter or higher who took rosuvastatin 20 mg daily for 2 years if they are similar to the patients in the JUPITER [[randomized controlled trial]] ([[Number needed to treat]] is 170).<ref name="pmid18997196">{{cite journal |author=Ridker PM, Danielson E, Fonseca FA, ''et al'' |title=Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein |journal=N. Engl. J. Med. |volume= |issue= |pages= |year=2008 |month=November |pmid=18997196 |doi=10.1056/NEJMoa0807646 |url= |issn=}}</ref><ref name="pmid14609996">{{cite journal |author=Ridker PM |title=Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial |journal=Circulation |volume=108 |issue=19 |pages=2292–7 |year=2003 |month=November |pmid=14609996 |doi=10.1161/01.CIR.0000100688.17280.E6 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=14609996 |issn=}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 00:02, 12 November 2008
Hydroxymethylglutaryl-coenzyme A reductase inhibitors, also called statins, are "compounds that inhibit HMG-CoA reductases, which reduce the chemical 3-hydroxy-3-methyl-glutaryl CoA. They have been shown to directly lower cholesterol synthesis.[1]
Classification
The following classification has been proposed based on molecular structure:[2][3]
Type 1
Type 1 statins (e.g., mevastatin, lovastatin, pravastatin, simvastatin) bind to HMG-CoA reductase using a decalin ring.
Type 2
Type 2 statins (e.g., fluvastatin, cerivastatin, atorvastatin, and rosuvastatin) bind to HMG-CoA reductase using a fluorophenyl group.
Effectiveness
Statin therapy benefits about 1 of every 24 diabetic patients who use the treatment for 5 years if they are similar to the patients in the meta-analysis by Kearney et al (Number needed to treat is 24).[4]
Statin therapy benefits about 1 of every 170 patients with LDL cholesterol less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher who took rosuvastatin 20 mg daily for 2 years if they are similar to the patients in the JUPITER randomized controlled trial (Number needed to treat is 170).[5][6]
References
- ↑ Anonymous. Hydroxymethylglutaryl-coenzyme A reductase inhibitors. National Library of Medicine. Retrieved on 2008-01-18.
- ↑ Istvan ES, Deisenhofer J (2001). "Structural mechanism for statin inhibition of HMG-CoA reductase". Science 292 (5519): 1160–4. DOI:10.1126/science.1059344. PMID 11349148. Research Blogging.
- ↑ Istvan E (2003). "Statin inhibition of HMG-CoA reductase: a 3-dimensional view". Atheroscler Suppl 4 (1): 3–8. PMID 12714031. [e]
- ↑ Kearney PM, Blackwell L, Collins R, et al (2008). "Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis". Lancet 371 (9607): 117–25. DOI:10.1016/S0140-6736(08)60104-X. PMID 18191683. Research Blogging.
- ↑ Ridker PM, Danielson E, Fonseca FA, et al (November 2008). "Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein". N. Engl. J. Med.. DOI:10.1056/NEJMoa0807646. PMID 18997196. Research Blogging.
- ↑ Ridker PM (November 2003). "Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial". Circulation 108 (19): 2292–7. DOI:10.1161/01.CIR.0000100688.17280.E6. PMID 14609996. Research Blogging.